{"name":"Proveca Pharma Limited","slug":"proveca-pharma-limited","ticker":"","exchange":"","domain":"","description":"Proveca Pharma Limited is a specialty pharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company's lead product, Sialanar, is currently marketed for the treatment of sialorrhea (excessive drooling) in patients with neurological disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sialanar","genericName":"Sialanar","slug":"sialanar","indication":"Chronic obstructive lung disease","status":"marketed"}]}],"pipeline":[{"name":"Sialanar","genericName":"Sialanar","slug":"sialanar","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","indications":["Chronic obstructive lung disease","Excessive salivation","General anesthesia","Hyperhidrosis of axilla","Peptic ulcer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNcFZrOUhyem5tdTU2SVhvWU01ZUJKSTdKdk1jajgySkZNTVB4VF9SNHpBMTZHUFB5VDRDMGtGeDBuUmp0N0JNTjFqU3hoTE9SaGQzd2ozc0tkbXJtNGdUSzAzMXFKQmFfSTRqSmpFTDI1SVlUSjlGM2JRcy1WS1lJaGlpZVJWeXJGREVlemYwV2RBdU92LVdsOW8yVjlhV0NYcHc?oc=5","date":"2026-03-27","type":"regulatory","source":"Medscape","summary":"EMA Backs Orodispersible Furosemide for Edema in Children - Medscape","headline":"EMA Backs Orodispersible Furosemide for Edema in Children","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQaF9YZzNrbUZaT21uazUwVHFmOWdSNFg1YnlUMVpkejhwRnpkaGtMdzIxb1pTbWN2SENxR3daOUZBc2ItaVZyZFJuR0dqeWxVOHVvRjhXRW9KS1R6WmlLUEdqZHVSaURwY2E0VEswbENSQWNhUmFKOW1jMEdYd2F2V1pZMUJKRHBVSlJuc2FJaDR3dGEwcWVKYmk0SWlna054Ry1BS3BrNzk2U2owOEhPM3FtSQ?oc=5","date":"2026-03-27","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026 - European Medicines ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNTnJ0RnBPczVqc2gtNmJ0WDI0T2dBaFgwb2NmY2tBQ0kwVE45aUNDMm9lbm9BbE1RRWhYZEl3djl3bzFLYkNKM2NkRjRxM2xUMWtOZUpHaVZmdDZSWWJTMFVkRzRBbElpOW54MUhmZ1dNQU5US0JTLWN3YW9BMy04SXlPeGtXN0pGMXJ6S3JIXy1NU3B6OThjN0Q1dlNzYk0?oc=5","date":"2026-03-27","type":"regulatory","source":"The Pharma Letter","summary":"Five novel meds recommended for approval by EMA’s CHMP - The Pharma Letter","headline":"Five novel meds recommended for approval by EMA’s CHMP","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOVmVwNzA3ZUduRmt2eHFULTN6Xzh0U0Q1OHZpQXV3bUU2OWw3ejF4OHVhTFNpdGUxSVlpYVFwMmc4VWh0UmY4S0ZZYlQ2TTVZVy12UzhHcGFmOXpXd0xlaXlCNThlVnktVG5XZEg3VmpsYTJNOE5taXYzR0s0bnZuaXYzSHZrRVJCTDBfZ0hpSEVjd3dj?oc=5","date":"2025-10-02","type":"pipeline","source":"thepharmacist.co.uk","summary":"Eight products granted special container status - thepharmacist.co.uk","headline":"Eight products granted special container status","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-07-08","type":"pipeline","source":"Daily Mail","summary":"The tiny tablet that baby heart patients can swallow - dispersing in saliva to help lower blood pressure and bolster blood flow - Daily Mail","headline":"The tiny tablet that baby heart patients can swallow - dispersing in saliva to help lower blood pressure and bolster blo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaDVWTERTTnQ1UUxfUTFNQ3BGeGdPT0RQTm1vanBoSkRoeEphblF3SUxxREoycV9RanRmVGZHM0JjTmdqd2tlOTk2OTZ5LUNmNDBCWHRlY2F1d0VBQnFuUWxqd2JYX2JXMzJtVXNySHNJUENDMnJWNktJdy04WmJEYWRVbkpEa1htaWVpSWNGcw?oc=5","date":"2024-02-08","type":"pipeline","source":"Frontiers","summary":"Editorial: Novel Mechanisms of Epileptogenesis and Its Inspired Pharmaceutical Treatments for Epilepsy - Frontiers","headline":"Editorial: Novel Mechanisms of Epileptogenesis and Its Inspired Pharmaceutical Treatments for Epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFA0S1paYzhjU1huTFdMbm9rRFhpV3lURDd5d0xpWDhkZmUwbHo2UGVUNVhZWE9NX1Z1ZldjSnRIWTJ6bjRHaWJFSmltbFVqeXotcWhOS0Y5OWQ4aWFmUERFTVVmVUJsVGUzQTNj?oc=5","date":"2024-01-12","type":"trial","source":"Wiley Online Library","summary":"Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial - Wiley Online Library","headline":"Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdHBYM2tCMUVERmtMQUtaM00ycmdYVWVLZnFscldZQ2ZDb0FQNWh4cExROXR2T18xb3M0a0RtZHF1cGhRQkhfV0lBRjFXRU1ZNnlEbGh4NXdXem43bVQ5dmI1QWlacWRKdzdXaC1fNjc5c3F6YVJ3NURYMlAyTkJyWkpGdkljV2pWUGVRRGlubGk0VUF4c3Bsal9VTTNNQVpaSjB6cno5aThlZ1FQeGJIc0N5WFpTZTVU?oc=5","date":"2023-09-15","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 - European Medici","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}